Skip to main content
. 2017 Apr 7;8(30):49033–49043. doi: 10.18632/oncotarget.16931

Figure 1.

Figure 1

(A) CCK-8 was used to determine NSCLC cell viability following treatment with 0, 0.625, 1.25, 2.5, 5, or 10 μM WP1130 alone. WP1130 concentrations of ≥ 2.5 μM had significant inhibitory effects on NSCLC cell proliferation, but 0–1.25 μM WP1130 did not. *P < 0.05, ****P < 0.0001 vs. 0 μM WP1130. (B) WP1130 co-treatment increased A549 and HCC827 cell sensitivity to cisplatin. Cisplatin sensitivity in NCI-H1299 cells treated with cisplatin alone and with cisplatin and WP1130 co-treatment did not differ.